Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 155 • 2017 Pediatric Rheumatology Symposium
A Single Center Review of Health Related Quality of Life in Children with Systemic Lupus Erythematosus Using the Pediatric Quality of Life Inventory Version 4.0 Generic Core Scale
JaLeen Rogers¹, Anna Carmela P. Sagcal-Gironella², Patricia Rosillo³, Andrea A. Ramirez⁴, Rosa Banuelos⁵ and Marietta M. de Guzman⁶, ¹Outcomes and Impact Services, Texas Children's Hospital, Houston, TX, ²Rheumatology, Texas Children's Hospital, Houston, TX, ³Allergy, Immunology and Rheumatology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ⁴Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ⁵Texas Children's Hospital, Houston, TX, ⁶Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Systemic lupus erythematosus (SLE) can cause adverse effects in various aspects of daily functioning for pediatric patients. Measuring Health-related Quality of Life (HRQOL) provides…
Abstract Number: 1383 • 2016 ACR/ARHP Annual Meeting
ANTI-RO/SSA and/or ANTI-La/SSB Antibodies: Association with Mild LUPUS Manifestations in 645 Childhood-Onset Systemic LUPUS Erythematosus
Glaucia V. Novak¹, Mariana Marques², Verena Balbi², Natali W. Gormezano², Katia T. Kozu², Ana Paula Sakamoto³, Rosa M R Pereira⁴, Maria Teresa Terreri³, Claudia S. Magalhães⁵, Silvana B. Sacchetti Sr.⁶, Adriana M E Sallum², Roberto Marini Sr.⁷, Virgínia Ferriani⁸, Cássia M. Barbosa⁹, Tânia C M Castro¹⁰, Valéria C. Ramos¹¹, Eloisa Bonfá¹² and Clovis A Silva¹³, ¹Pediatric Rheumatology Unit,, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil, ⁴Rheumatology, University of São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP), Botucatu, Brazil, ⁶Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁸Department of Pediatrics School of Medicine of Ribeirão Preto, University of São Paulo (USP-RP), Ribeirão Preto, Brazil, ⁹Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹⁰Pediatric Rheumatology Unit, Hospital Menino Jesus, São Paulo, Brazil, ¹¹Pediatric Rheumatology Unit, Pontifical Catholic University of Sorocaba, São Paulo, Brazil, ¹²Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ¹³Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-Ro/SSA and anti-La/SSB antibodies were reported in 30-50% and 10-30% of adult SLE patients, associated mainly with cutaneous manifestations. However, to our knowledge there…
Abstract Number: 1386 • 2016 ACR/ARHP Annual Meeting
Outcome of 847 Childhood-Onset Systemic LUPUS Erythematousus Patients in Three Age Groups
Sandra R M Lopes¹, Natali W. Gormezano², Roberta C. Gomes Sr.³, Nadia E Aikawa⁴, Rosa M R Pereira⁵, Maria Teresa Terreri⁶, Claudia S. Magalhães⁷, Eunice M. Okuda⁸, Ana Paula Sakamoto⁶, Adriana M E Sallum², Simone Appenzeller⁹, Virgínia Ferriani¹⁰, Cássia M. Barbosa¹¹, Simone Lotufo¹², Adriana A. Jesus^13,14, Luis E C Andrade¹⁵, Lucia M A Campos⁴, Eloisa Bonfa¹⁶ and Clovis A Silva³, ¹Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, University of São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ⁶Pediatric Rheumatology Unit, Federal University of São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Division, São Paulo State University (UNESP), Botucatu, Brazil, ⁸Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ⁹Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil, ¹⁰Department of Pediatrics School of Medicine of Ribeirão Preto, University of São Paulo (USP-RP), Ribeirão Preto, Brazil, ¹¹Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹²Pediatric Rheumatology Unit, Hospital Municipal Infantil Menino Jesus, São Paulo, Brazil, ¹³Pediatrics Department, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Pediatrics, Instituto da Criança da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, ¹⁵Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁶Rheumatology Divison, Hospital das Clinicas, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
Background/Purpose: A recent large study comparing childhood systemic lupus erythematosus (cSLE) with adult-onset SLE revealed a more aggressive and worse outcome in the former group.…
Abstract Number: 1392 • 2016 ACR/ARHP Annual Meeting
Familial Aggregation of Autoimmune Diseases in Childhood and Adulthood Systemic Lupus Erythematosus
Nailu A. Sinicato¹, Luciana de Oliveira², Aline Tamires Lapa², Lilian Tereza Costallat³, Roberto Marini Sr.⁴, Timothy B. Niewold⁵ and Simone Appenzeller⁶, ¹Pediatrics, State University of Campinas, Campinas, Brazil, ²Medicine, State University of Campinas, Campinas, Brazil, ³RUA EZEQUIEL MAGALHAES,26, Unicamp, Campinas, Brazil, ⁴Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ⁵Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁶Pediatric Rheumatology Unit, State University of Campinas, Campinas, Brazil
Background/Purpose: Genetic factors play a role in SLE, evidenced by the high sibling risk ratio (λs=8–29) and higher concordance rates between monozygotic twins (>35%) compared…
Abstract Number: 1813 • 2016 ACR/ARHP Annual Meeting
Prevalence and Incidence of Systemic Lupus Erythematosus in Tucuman -Argentina
Luciana Gonzalez Lucero¹, Raul Sueldo², Alberto Ives Torres³, Alexia Cristofari³, Ana Lucía Barbaglia³, Ana Olea³, Ana Quinteros⁴, Gladys Seleme³, Francisco Colombres³, Dora Lia Vásquez³, Gustavo Arquez³, Gustavo Alberto Carrizo³, Hector Lazaro³, Maria Josefina Molina³, Laura Juarez³, Maria Constanza Bertolaccini⁵, Maria Olga Leal⁶, María Silvia Yacuzzi², Mariana Espindola Echazu³, Norma Robles De Garrone³, Rodolfo Orlando Dip³, Olga Romano³, Oscar Pera³, Silvia Paz³, Veronica Bellomio⁷, Maximiliano Machado Escobar², Silvia Rengel⁸, Liliana Galindo⁷, Mirta Santana² and Eleonora Lucero², ¹Rheumatology Unit, Hospital Padilla, Tucumán, Tucumán, Argentina, ²Hospital Angel Cruz Padilla, Tucumán, Argentina, ³Sociedad de Reumatología de Tucumán, tucuman, Argentina, ⁴Centro Integral Reumatológico, Tucuman, Argentina, ⁵Rheumatology, Hospital Angel Cruz Padilla, Tucumán, Argentina, ⁶Centro Integral De Reumatologia, Tucumán, Argentina, ⁷Hospital Ángel Cruz Padilla, Tucuman, Argentina, ⁸Hospital Centro de Salud, Tucuman, Argentina
Background/Purpose: Systemic Lupus Erythematosus (SLE) is the paradigm of the autoimmune diseases that primarily affects women in a ratio of 9: 1. In England and…
Abstract Number: 1814 • 2016 ACR/ARHP Annual Meeting
Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE)
Gabriela García-Guevara¹, Ricardo Ríos-Corzo², Hilda Fragoso-Loyo³, Juan Jakez-Ocampo⁴, John Hernandez-Flores², Mariana Lopez-Lopez⁵, Eduardo Carrillo-Maravilla⁶, Jose Sifuentes-Osornio² and Yemil Atisha-Fregoso⁷, ¹Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁶Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁷Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Pneumonia, remains as a main cause of mortality in patients with SLE. There are not specific guidelines for the empiric treatment in these patients.…
Abstract Number: 1842 • 2016 ACR/ARHP Annual Meeting
Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients
Yifang Mei, Xiaoping Sun, Yuxia Shao, Huanhuan Zhan and Zhiyi Zhang, Department of Rheumatology, The First Affiliated Hospital of Harbin Medical University, Harbin, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a kind of chronic and autoimmune disease with variable multi-system involvement of unknown causes, which is characterized by periods…
Abstract Number: 2791 • 2016 ACR/ARHP Annual Meeting
Targeting Micro-RNAs Derived from Extracellular Vesicles to Inhibit of TLR7 and TLR8 Signaling Suppresses Inflammation in a Novel Human-Mouse Chimeric Model of Systemic Lupus Erythematosus
Nicholas A. Young¹, Giancarlo R. Valiente², Holly Steigelman³, Jeffrey Hampton⁴ and Wael N. Jarjour⁵, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University, Columbus, OH, ⁴Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Department of Rheumatology/Medicine, Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease displaying a heavy female predominance during reproductive years. We have previously shown that toll-like receptor…
Abstract Number: 2812 • 2016 ACR/ARHP Annual Meeting
Clinical Trial Simulation Identifies Factors for Patient Engagement in Systemic Lupus Erythematosus and Lupus Nephritis Trials By African-Americans
S. Sam Lim¹, Doug McKinnell², M Edward Pierson³ and Faye O'Brien³, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²Deloitte UK Life Sciences Advisory, London, United Kingdom, ³AstraZeneca, Gaithersburg, MD
Background/Purpose: Clinical trials of patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) can be confounded by difficulties in engaging patients. Identifying factors of…
Abstract Number: 747 • 2015 ACR/ARHP Annual Meeting
Depletion of Serum Soluble CD40L Characterizes the Association Between Systemic Lupus Erythematosus and Thrombotic Thrombocytopenic Purpura: Longitudinal, Single-Center Study
Javier Merayo-Chalico¹, Ana Barrera-Vargas², Jorge Alcocer-Varela² and Diana Gómez-Martín², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher incidence of thrombotic thrombocytopenic purpura (TTP). Differentiating TTP from SLE activity may represent a challenge…
Abstract Number: 780 • 2015 ACR/ARHP Annual Meeting
Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus
Yoko Wada¹, Hisashi Hasegawa², Takeshi Kuroda³, Masaaki Nakano⁴ and Ichiei Narita¹, ¹Department of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata City General Hospital, Niigata, Japan, ³Health Administration Center, Niigata University, Niigata, Japan, ⁴Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by fluctuating disease activity over periods of years. The estimated 5-year survival rate of…
Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting
Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark^1,2, ¹Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…
Abstract Number: 2935 • 2015 ACR/ARHP Annual Meeting
Disease Evolution in Late Onset and Early Onset Systemic Lupus Erythematosus (SLE)
Roa'a Al Johani¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: To compare clinical features, disease activity and outcome in late onset versus early onset SLE over 5 years of follow up. Methods: Patients with…
Abstract Number: 2953 • 2015 ACR/ARHP Annual Meeting
The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?
Kimberly Trotter¹, Kichul Ko¹, Gabrielle Liu¹ and Tammy Utset², ¹Medicine, University of Chicago, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: There is sparse data examining the characteristics of SLE patients who frequent the emergency room (ER). Data suggest that lupus patients with certain sociodemographic…
Abstract Number: 3218 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
William Stohl¹, Andreas Schwarting², Masato Okada³, Morton Scheinberg⁴, Andrea Doria⁵, Anne Hammer⁶, Christi Kleoudis⁷, Damon Bass⁸, James Groark⁹, Norma Lynn Fox¹⁰, David Roth¹¹ and David Gordon¹¹, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²ACURA Kliniken, Bad Kreuznach, Germany, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ⁵Division of Rheumatology, University of Padova, Padova, Italy, ⁶GlaxoSmithKline, Research Triangle Park, NC, ⁷Parexel, Durham, NC, ⁸Immuno-Inflammation, GlaxoSmithKline, King of Prussia, PA, ⁹GlaxoSmithKline, Philadelphia, NC, ¹⁰GlaxoSmithKline, Washington, MD, ¹¹GlaxoSmithKline, Philadelphia, PA
Background/Purpose: To assess the efficacy and safety of belimumab (BEL) administered subcutaneously plus standard SLE care (SoC) in patients with active SLE.Methods: BLISS-SC (BEL112341; NCT01484496)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].